TY - JOUR
T1 - GLP-1 analogues treatment was not associated with additional weight loss over intensive lifestyle intervention in severely obese patients with type 2 diabetes
AU - Tahrani, A.
AU - Wright, A.
AU - Kempegowda, P.
AU - Abernethy, G.
AU - Sadiqi, H.
AU - Phillips, C.
AU - McLease, J.
AU - Golics, R.
AU - Maxwell, E.
AU - John, R.
AU - Shakher, J.
AU - Bellary, S.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Clinical trials of GLP-1 analogues in patients with type 2 diabetes (T2D) typically exclude patients with a BMI >40 kg/m² and do not include intensive lifestyle intervention (ILI). We aimed to assess the impact of GLP-1 analogues on weight in severely obese patients with T2D undergoing ILI. We conducted an observational cohort study of severely obese adults with T2D attending ILI at a tertiary bariatric centre for 12 months. All patients who received GLP-1 analogues for at least 6 months (GLP+) were included and were age, gender and BMI matched to patients with T2D attending the same ILI who did not receive GLP-1 (GLP−). One hundred fifty-five patients were included [GLP+ vs. GLP−: Number 121 vs. 34; Age: 52.6 ± 10.0 vs. 53.7 ± 10.8 years, p = 0.6; median (IQR) BMI: 45.0 (41.7–50.8) vs. 46.4 (43.0–50.6) kg/m2, p = 0.4; Weight: 127.9 ± 22.6 vs. 132.4 ± 25.2, p = 0.3; Women: 62.8% vs. 70.6%, p = 0.4; current smoking 16.1% vs. 13.8%, p = 0.4; Insulin treatment 36.4% vs. 20.6%, p = 0.1]. GLP-1 analogues treatment duration was 10.3 ± 2.8 months. There was no difference in weight loss between groups (GLP− vs. GLP+) (−7.8 ± 8.2 vs. −7.6 ± 8.7 kg, p = 0.9; as a % of baseline weight −6.1 ± 6.2% vs. −5.9 ± 6.8%, p = 0.9). After adjusting for baseline weight, and the use of insulin, orlistat, sulphonylureas, DPP-4 inhibitors and thiazolidinediones, GLP-1 analogues treatment was not associated with weight change (B = −1.4, p = 0.5). In conclusion, in this observational analysis GLP-1 analogues did not offer additional weight loss over and above that achieved by ILI in severely obese patients with T2D.
AB - Clinical trials of GLP-1 analogues in patients with type 2 diabetes (T2D) typically exclude patients with a BMI >40 kg/m² and do not include intensive lifestyle intervention (ILI). We aimed to assess the impact of GLP-1 analogues on weight in severely obese patients with T2D undergoing ILI. We conducted an observational cohort study of severely obese adults with T2D attending ILI at a tertiary bariatric centre for 12 months. All patients who received GLP-1 analogues for at least 6 months (GLP+) were included and were age, gender and BMI matched to patients with T2D attending the same ILI who did not receive GLP-1 (GLP−). One hundred fifty-five patients were included [GLP+ vs. GLP−: Number 121 vs. 34; Age: 52.6 ± 10.0 vs. 53.7 ± 10.8 years, p = 0.6; median (IQR) BMI: 45.0 (41.7–50.8) vs. 46.4 (43.0–50.6) kg/m2, p = 0.4; Weight: 127.9 ± 22.6 vs. 132.4 ± 25.2, p = 0.3; Women: 62.8% vs. 70.6%, p = 0.4; current smoking 16.1% vs. 13.8%, p = 0.4; Insulin treatment 36.4% vs. 20.6%, p = 0.1]. GLP-1 analogues treatment duration was 10.3 ± 2.8 months. There was no difference in weight loss between groups (GLP− vs. GLP+) (−7.8 ± 8.2 vs. −7.6 ± 8.7 kg, p = 0.9; as a % of baseline weight −6.1 ± 6.2% vs. −5.9 ± 6.8%, p = 0.9). After adjusting for baseline weight, and the use of insulin, orlistat, sulphonylureas, DPP-4 inhibitors and thiazolidinediones, GLP-1 analogues treatment was not associated with weight change (B = −1.4, p = 0.5). In conclusion, in this observational analysis GLP-1 analogues did not offer additional weight loss over and above that achieved by ILI in severely obese patients with T2D.
U2 - 10.1016/j.appet.2014.12.169
DO - 10.1016/j.appet.2014.12.169
M3 - Abstract
SN - 0195-6663
VL - 87
SP - 393
EP - 393
JO - Appetite
JF - Appetite
ER -
